Web20 uur geleden · Hayley Widden, PhD’S Post Hayley Widden, PhD Oncology Medical Science Liaison 3h Edited Web25 apr. 2024 · Merus is the sponsor of the clinical trial, investigating Peto, and certain preclinical work described in the Nature Cancer paper was generated in conjunction with …
Did you know?
WebMerus is an equal employment opportunity employer that does not discriminate on the basis of actual or perceived race, color, religious creed, national origin, sex (including … Web14 apr. 2024 · 4:10 PM: Merus Announces Publication of an Abstract on Petosemtamab in Advanced Gastric/Esophageal Adenocarcinoma for Presentation at the AACR ...
Web5 uur geleden · UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing... Web14 mrt. 2024 · Merus Announces Publication of an Abstract on Preclinical Mechanism of Action of MCLA-129 Selected for Poster Presentation at the AACR Annual Meeting 2024 A Merus B.V.
Web5 uur geleden · ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ®), today announced the publication of an abstract for a … Web5 uur geleden · UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) — Merus N.V. M MRUS (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract for a …
Web26 okt. 2024 · Webcast link: available on our website. Dial-in: Toll-free: 1 (800) 715-9871 / International: 1 (646) 307-1963. Conference ID: 1694377. About MCLA-129. MCLA-129 is an antibody-dependent cellular ...
Web5 uur geleden · ET UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the publication of an abstract for a … sugar monitor without finger pricksWebInvestegate announcements from Merus N.V., Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at the AACR Annual Meeting 2024 and Provides a Program and Regulatory Update paint with a sprayerWeb14 apr. 2024 · Merus N.V. today announced the publication of an abstract for a plenary session oral presentation of interim clinical data on the bispecific antibody petosemtamab … sugar monitor on armWeb14 apr. 2024 · Merus annonce la publication d'un résumé sur le mécanisme d'action préclinique du MCLA-.. GL. 16/03: Merus présente le pétosemtamab dans un résumé sur le carcinome à cellules squameuses ... sugar mother dating siteWebMerus is an equal employment opportunity employer that does not discriminate on the basis of actual or perceived race, color, religious creed, national origin, sex (including pregnancy, childbirth, and related medical conditions), sexual orientation, age, ancestry, disability or perceived disability, qualified handicap, gender identity, military status, veteran status, … paint with arts and culterWeb14 apr. 2024 · UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 14, 2024 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or … sugar moon rb mine by designWebMerus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics ®. Multiclonics … paint with a purpose